Genmab: Bryan Garnier reiterates 'buy' - readjusts FV.
(CercleFinance.com) - Bryan Garnier has reiterated its "buy" rating on Genmab while "readjusting" its fair value on the shares to from 2072 Danish kronor 1680 Danish kronor, after the biotechnology company announced reporting one billion in Darzalex sales over a year, giving the anti-tumor drug blockbuster status.
"Notwithstanding, the potential for this antibody remains very broad with Genmab planning, after multiple myeloma, to explore solid cancers," the brokerage firm writes in a research report.
Bryan Garnier points out that the company recently announced the approval of Darzalex in Japan, on top of last year's approvals - first in Europe then the US.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"Notwithstanding, the potential for this antibody remains very broad with Genmab planning, after multiple myeloma, to explore solid cancers," the brokerage firm writes in a research report.
Bryan Garnier points out that the company recently announced the approval of Darzalex in Japan, on top of last year's approvals - first in Europe then the US.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.